Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 4/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.49 |
| ▸ | MELK | Q14680 | 1/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659264 | 0.90 | PAX8 (0.55) | PAX8EGFRCSF1RMAPTNUDT1 | |
| SCHEMBL3792946 | 0.90 | NUDT1 (0.60) | PAX8EGFRCSF1RNUDT1CREBBP | |
| SCHEMBL3786537 | 0.89 | PAX8 (0.50) | PAX8EGFRMAPTNUDT1MELK | |
| SCHEMBL403679 | 0.89 | PAX8 (0.52) | PAX8EGFRCSF1RNUDT1CREBBP | |
| SCHEMBL401899 | 0.87 | CSF1R (0.55) | PAX8EGFRCSF1RNUDT1CREBBP | |
| SCHEMBL29744204 | 0.87 | CSF1R (0.55) | PAX8EGFRCSF1RNUDT1CREBBP | |
| SCHEMBL13082917 | 0.86 | EGFR (0.61) | PAX8EGFRCSF1RMAPTMELK | |
| Hydrochloric Acid SCHEMBL15094014 | 0.86 | PAX8 (0.56) | PAX8EGFRCSF1RNUDT1CREBBP | |
| SCHEMBL3790489 | 0.86 | MAPT (0.71) | PAX8MAPTCREBBPGAAKDM4E | |
| SCHEMBL23589718 | 0.84 | NUDT1 (0.68) | PAX8CSF1RNUDT1CREBBPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031723-A1 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases | CLANOTECH AB (SE) | 2015-01-29 | — | — | US | claimed |
| WO-2013103317-A1 | QUINOLINE COMPOUNDS WHICH ARE ANTI-ANGIOGENIC INTEGRIN ALPHA5 BETAL INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS OR FIBROSIS-RELATED DISEASES | CLANOTECH AB (SE) | 2013-07-11 | — | — | WO | claimed |
| WO-2010133672-A1 | DERIVATIVES OF QUINOLINE-3-CARBOXYLIC ACID AND THEIR MEDICAL USE | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | claimed |
| US-9376393-B2 | Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases | CLANOTECH AB (SE) | 2016-06-28 | — | — | US | disclosed |
| US-9376393-B2 | Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases | CLANOTECH AB (SE) | 2016-06-28 | — | — | US | disclosed |
| US-9376393-B2 | Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases | CLANOTECH AB (SE) | 2016-06-28 | — | — | US | disclosed |
| US-20150031723-A1 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases | CLANOTECH AB (SE) | 2015-01-29 | — | — | US | disclosed |
| US-20150031723-A1 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases | CLANOTECH AB (SE) | 2015-01-29 | — | — | US | disclosed |
| US-20150031723-A1 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases | CLANOTECH AB (SE) | 2015-01-29 | — | — | US | disclosed |
| WO-2010133672-A1 | DERIVATIVES OF QUINOLINE-3-CARBOXYLIC ACID AND THEIR MEDICAL USE | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031723-A1 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases | ITGB5, ITGA5, ITGAL | PAX8 381/4885EGFR 3274/4885CSF1R 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.